STÖCKEMANN Klaus
No ORCID on file
· 344 papers in corpus
1997
A combined pharmaceutical preparation contains LHRH-analogous substances and anti-estrogens with tissue-selective estrogenic effect. Also disclosed is the use of this combined pharmaceutical preparation to treat gynaecological disorders, in…
1997
A combined pharmaceutical preparation contains LHRH-analogous substances and anti-estrogens with tissue-selective estrogenic effect. Also disclosed is the use of this combined pharmaceutical preparation to treat gynaecological disorders, in…
1997
A combined pharmaceutical preparation contains LHRH-analogous substances and anti-estrogens with tissue-selective estrogenic effect. Also disclosed is the use of this combined pharmaceutical preparation to treat gynaecological disorders, in…
1997
A combined pharmaceutical preparation contains LHRH-analogous substances and anti-estrogens with tissue-selective estrogenic effect. Also disclosed is the use of this combined pharmaceutical preparation to treat gynaecological disorders, in…
1997
A combined pharmaceutical preparation contains LHRH-analogous substances and anti-estrogens with tissue-selective estrogenic effect. Also disclosed is the use of this combined pharmaceutical preparation to treat gynaecological disorders, in…
1997
A combined pharmaceutical preparation contains LHRH-analogous substances and anti-estrogens with tissue-selective estrogenic effect. Also disclosed is the use of this combined pharmaceutical preparation to treat gynaecological disorders, in…
1997
A combined pharmaceutical preparation contains LHRH-analogous substances and anti-estrogens with tissue-selective estrogenic effect. Also disclosed is the use of this combined pharmaceutical preparation to treat gynaecological disorders, in…
1997
A combined pharmaceutical preparation contains LHRH-analogous substances and anti-estrogens with tissue-selective estrogenic effect. Also disclosed is the use of this combined pharmaceutical preparation to treat gynaecological disorders, in…
1997
A combined pharmaceutical preparation contains LHRH-analogous substances and anti-estrogens with tissue-selective estrogenic effect. Also disclosed is the use of this combined pharmaceutical preparation to treat gynaecological disorders, in…
1997
A combined pharmaceutical preparation contains LHRH-analogous substances and anti-estrogens with tissue-selective estrogenic effect. Also disclosed is the use of this combined pharmaceutical preparation to treat gynaecological disorders, in…
1997
A combined pharmaceutical preparation contains LHRH-analogous substances and anti-estrogens with tissue-selective estrogenic effect. Also disclosed is the use of this combined pharmaceutical preparation to treat gynaecological disorders, in…
1997
A combined pharmaceutical preparation contains LHRH-analogous substances and anti-estrogens with tissue-selective estrogenic effect. Also disclosed is the use of this combined pharmaceutical preparation to treat gynaecological disorders, in…
1997
A combined pharmaceutical preparation contains LHRH-analogous substances and anti-estrogens with tissue-selective estrogenic effect. Also disclosed is the use of this combined pharmaceutical preparation to treat gynaecological disorders, in…
1997
A combined pharmaceutical preparation contains LHRH-analogous substances and anti-estrogens with tissue-selective estrogenic effect. Also disclosed is the use of this combined pharmaceutical preparation to treat gynaecological disorders, in…
1997
A combined pharmaceutical preparation contains LHRH-analogous substances and anti-estrogens with tissue-selective estrogenic effect. Also disclosed is the use of this combined pharmaceutical preparation to treat gynaecological disorders, in…
1997
A combined pharmaceutical preparation contains LHRH-analogous substances and anti-estrogens with tissue-selective estrogenic effect. Also disclosed is the use of this combined pharmaceutical preparation to treat gynaecological disorders, in…
1997
A combined pharmaceutical preparation contains LHRH-analogous substances and anti-estrogens with tissue-selective estrogenic effect. Also disclosed is the use of this combined pharmaceutical preparation to treat gynaecological disorders, in…
1997
A combined pharmaceutical preparation contains LHRH-analogous substances and anti-estrogens with tissue-selective estrogenic effect. Also disclosed is the use of this combined pharmaceutical preparation to treat gynaecological disorders, in…
1997
A combined pharmaceutical preparation contains LHRH-analogous substances and anti-estrogens with tissue-selective estrogenic effect. Also disclosed is the use of this combined pharmaceutical preparation to treat gynaecological disorders, in…
1997
A combined pharmaceutical preparation contains LHRH-analogous substances and anti-estrogens with tissue-selective estrogenic effect. Also disclosed is the use of this combined pharmaceutical preparation to treat gynaecological disorders, in…
1997
A combined pharmaceutical preparation contains LHRH-analogous substances and anti-estrogens with tissue-selective estrogenic effect. Also disclosed is the use of this combined pharmaceutical preparation to treat gynaecological disorders, in…
1997
A combined pharmaceutical preparation contains LHRH-analogous substances and anti-estrogens with tissue-selective estrogenic effect. Also disclosed is the use of this combined pharmaceutical preparation to treat gynaecological disorders, in…
1997
The present invention concerns the use of a product containing in combination individual dosage units of a competitive progesterone antagonist and individual dosage units of a gestagen to be sequentially orally administrated (the competitiv…
1997
The present invention concerns the use of a product containing in combination individual dosage units of a competitive progesterone antagonist and individual dosage units of a gestagen to be sequentially orally administrated (the competitiv…
1997
The present invention concerns the use of a product containing in combination individual dosage units of a competitive progesterone antagonist and individual dosage units of a gestagen to be sequentially orally administrated (the competitiv…